Screener
Veradermics MANE Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $20,925 | $11,447 |
| General and administrative | 8,937 | 1,468 |
| Total operating expenses | 29,862 | 12,915 |
| Loss from operations | (29,862) | (12,915) |
| Other income: | ||
| Interest income | 2,481 | 482 |
| Other income | 149 | 33 |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's other operating expenses?
- Veradermics (MANE) reported other operating expenses of $29.86M in Q1 2026.
- How has Veradermics's other operating expenses changed year-over-year?
- Veradermics's other operating expenses increased by 131.2% year-over-year, from $12.92M to $29.86M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Veradermics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude